Shares of MediciNova, Inc. (NASDAQ:MNOV) have earned a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that cover the stock, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy rating.
Analysts have set a twelve-month consensus price objective of $20.67 for the company and are forecasting that the company will post ($0.08) earnings per share for the current quarter, according to Zacks. Zacks has also assigned MediciNova an industry rank of 87 out of 255 based on the ratings given to related companies.
MNOV has been the topic of several analyst reports. BidaskClub cut MediciNova from a “sell” rating to a “strong sell” rating in a research report on Saturday, January 18th. ValuEngine upgraded MediciNova from a “hold” rating to a “buy” rating in a research report on Wednesday, October 2nd.
Shares of MediciNova stock opened at $6.44 on Tuesday. The business’s 50 day simple moving average is $7.04 and its 200-day simple moving average is $8.01. The stock has a market capitalization of $286.73 million, a price-to-earnings ratio of -25.76 and a beta of 1.16. MediciNova has a twelve month low of $6.36 and a twelve month high of $13.37.
MediciNova (NASDAQ:MNOV) last announced its quarterly earnings results on Friday, October 25th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.10. As a group, research analysts forecast that MediciNova will post -0.34 EPS for the current year.
MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction.
Further Reading: Do You Need a Fiduciary?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.